1. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models
- Author
-
Giulietta Maruggi, Corey P. Mallett, Jason W. Westerbeck, Tiffany Chen, Giuseppe Lofano, Kristian Friedrich, Lin Qu, Jennifer Tong Sun, Josie McAuliffe, Amey Kanitkar, Kathryn T. Arrildt, Kai-Fen Wang, Ian McBee, Deborah McCoy, Rebecca Terry, Alison Rowles, Maia Araujo Abrahim, Michael A. Ringenberg, Malcolm J. Gains, Catherine Spickler, Xuping Xie, Jing Zou, Pei-Yong Shi, Taru Dutt, Marcela Henao-Tamayo, Izabela Ragan, Richard A. Bowen, Russell Johnson, Sandra Nuti, Kate Luisi, Jeffrey B. Ulmer, Ann-Muriel Steff, Rashmi Jalah, Sylvie Bertholet, Alan H. Stokes, and Dong Yu
- Subjects
COVID-19 Vaccines ,efficacy ,immunogenicity ,Antibodies, Viral ,Mice ,SARS-CoV-2 vaccine ,Cricetinae ,Drug Discovery ,Genetics ,Animals ,Humans ,Tissue Distribution ,RNA, Messenger ,biodistribution ,Molecular Biology ,Pharmacology ,SARS-CoV-2 ,toxicity ,COVID-19 ,Antibodies, Neutralizing ,Rats ,self-amplifying mRNA ,Liposomes ,Spike Glycoprotein, Coronavirus ,Nanoparticles ,Molecular Medicine ,Original Article - Abstract
RNA vaccines have demonstrated efficacy against SARS-CoV-2 in humans and the technology, is being leveraged for rapid emergency response. In this report, we assessed immunogenicity, and, for the first time, toxicity, biodistribution and protective efficacy in preclinical models of a two-dose self-amplifying messenger RNA (SAM) vaccine, encoding a prefusion stabilized Spike antigen of SARS-CoV-2 Wuhan-Hu-1 strain and delivered by lipid nanoparticles (LNP). In mice, one immunization with the SAM vaccine elicited a robust Spike-specific antibody response, which was further boosted by a second immunization, and effectively neutralized the matched SARS-CoV-2 Wuhan strain as well as B.1.1.7 (Alpha), B.1.351 (Beta) and B.1.617.2 (Delta) variants. High frequencies of Spike-specific germinal center B, Th0/Th1 CD4, and CD8 T cell responses were observed in mice. Local tolerance, potential systemic toxicity, and biodistribution of the vaccine were characterized in rats. In hamsters, the vaccine candidate was well-tolerated, markedly reduced viral load in the upper and lower airways, and protected animals against disease in a dose-dependent manner, with no evidence of disease enhancement following SARS-CoV-2 challenge. Therefore, the SARS-CoV-2 SAM (LNP) vaccine candidate has a favorable safety profile, elicits robust protective immune responses against multiple SARS-CoV-2 variants, and has been advanced to Phase-1 clinical evaluation (NCT04758962)., Graphical Abstract, Comprehensive preclinical development of a lipid nanoparticle (LNP)-formulated SAM vaccine encoding the prefusion stabilized SARS-CoV-2 Spike full-length antigen is reported. Protective efficacy, immunogenicity, toxicity, and biodistribution assessment of this candidate vaccine in mice, rats, and hamsters showed a favorable safety profile and robust immune responses against SARS-CoV-2 infection and disease.
- Published
- 2022
- Full Text
- View/download PDF